Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplant-MedSci.cn

Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplant

Lin, T; Hydutsky, L; Parros, H; Murphy, S; Pei, H; Londhe, A; Ukropec, J; Qi, M; Lutska, Y; Sharma, M

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务